Introduction
Bleomycin is an antibiotic with cytotoxic properties, commonly used in combination regimens for the treatment of Hodgkin’s and non-Hodgkin’s lymphoma. In addition to its antitumor activity, bleomycin is used as a sclerosant in the treatment of vascular malformations and in recurrent malignant pleural effusions (1). Bleomycin is mixtures included bleomycin A2, B2 and A5. Published protocols give bleomycin doses in milligrams (mg), international units (IU), or United States Pharmacopoeia units (USP units). Even though Jim Siderov has noted that dosage nomenclature of bleomycin need to be standardised to avoid errors in 2001 (2), the inconsistency in nomenclature seems to be universal in many countries including China. This inconsistency increases the risk of medication error. However, as far as we know no cases have reported. Here we present a case report of accidental bleomycin overdose with injection of bleomycin 150 USP (equivalent to ten times the common dose) as part of the doxorubicin, bleomycin, vindesine, dacarbazine protocol (ABVD). We present the following article in accordance with the CARE reporting checklist.